RESUMEN
Through inhibitory G protein-coupled melatonin receptors, melatonin regulates intracellular signaling systems and also the transcriptional activity of certain genes. Clock genes are proposed as regulatory factors in forming dopamine-related behaviors and mood and melatonin has the ability to regulate these processes. Melatonin-mediated changes in clock gene expression have been reported in brain regions, including the striatum, that are crucial for the development of dopaminergic behaviors and mood. However, it is not known whether melatonin receptors present in striatum mediate these effects. Therefore, we investigated the role of the melatonin/melatonin receptor system on clock gene expression using a model of primary neuronal cultures prepared from striatum. We found that melatonin at the receptor affinity range (i.e., nm) affects the expression of the clock genes mPer1, mClock, mBmal1 and mNPAS2 (neuronal PAS domain protein 2) differentially in a pertussis toxin-sensitive manner: a decrease in Per1 and Clock, an increase in NPAS2 and no change in Bmal1 expression. Furthermore, mutating MT1 melatonin receptor (i.e., MT1 knockouts, MT1(-/-)) reversed melatonin-induced changes, indicating the involvement of MT1 receptor in the regulatory action of melatonin on neuronal clock gene expression. Therefore, by controlling clock gene expression we propose melatonin receptors (i.e., MT1) as novel therapeutic targets for the pathobiologies of dopamine-related behaviors and mood.
Asunto(s)
Proteínas CLOCK/genética , Cuerpo Estriado/fisiología , Melatonina/fisiología , Neuronas/fisiología , Receptor de Melatonina MT1/genética , Análisis de Varianza , Animales , Factores de Transcripción con Motivo Hélice-Asa-Hélice Básico/biosíntesis , Factores de Transcripción con Motivo Hélice-Asa-Hélice Básico/genética , Factores de Transcripción con Motivo Hélice-Asa-Hélice Básico/metabolismo , Proteínas CLOCK/biosíntesis , Proteínas CLOCK/metabolismo , Células Cultivadas , Cuerpo Estriado/citología , Cuerpo Estriado/metabolismo , AMP Cíclico/metabolismo , Femenino , Masculino , Melatonina/metabolismo , Ratones , Ratones Endogámicos C3H , Ratones Endogámicos ICR , Ratones Noqueados , Proteínas del Tejido Nervioso/biosíntesis , Proteínas del Tejido Nervioso/genética , Proteínas del Tejido Nervioso/metabolismo , Neuronas/metabolismo , Proteínas Circadianas Period/biosíntesis , Proteínas Circadianas Period/genética , Proteínas Circadianas Period/metabolismo , Toxina del Pertussis/farmacología , ARN Mensajero/biosíntesis , ARN Mensajero/genética , Receptor de Melatonina MT1/biosíntesis , Receptor de Melatonina MT1/metabolismo , Receptor de Melatonina MT2/biosíntesis , Receptor de Melatonina MT2/genética , Receptor de Melatonina MT2/metabolismo , Reacción en Cadena de la Polimerasa de Transcriptasa InversaRESUMEN
The expression of 5-lipoxygenase (5-LOX) is affected by aging and regulated by epigenetic mechanisms including DNA methylation. We used methylation-sensitive restriction endonucleases (AciI, BstUI, HpaII, and HinP1I) to assess 5-LOX DNA methylation in brain and heart tissue samples from young (2 months) and old (22 months) mice. We also measured mRNA content for 5-LOX and the DNA methyltransferases DNMT1 and DNMT3a. In young mice, the 5-LOX mRNA content was significantly greater in the heart compared to the brain; 5-LOX DNA methylation was lower, except in the AciI assay in which it was higher in the heart. Aging decreased 5-LOX mRNA content in the heart and increased it in the brain. Aging also increased 5-LOX DNA methylation and this effect was site- (i.e., enzyme) and tissue-specific. Generally, DNMT1 and DNMT3a mRNA content was lower in the brain regions compared to the heart; the only effect of aging was observed in the mRNA content of DNMT3a, which was decreased in the heart of old mice. These results indicate a complex tissue-specific and aging-dependent interplay between the DNA methylation system and 5-LOX mRNA content. Interpretation of this data must take into account that the tissue samples contained a mixture of various cell types.
Asunto(s)
Envejecimiento/metabolismo , Araquidonato 5-Lipooxigenasa/genética , Encéfalo/enzimología , Metilación de ADN/genética , Miocardio/enzimología , ARN Mensajero/metabolismo , Envejecimiento/genética , Animales , ADN (Citosina-5-)-Metiltransferasa 1 , ADN (Citosina-5-)-Metiltransferasas/metabolismo , ADN Metiltransferasa 3A , Regulación hacia Abajo/genética , Epigénesis Genética/fisiología , Silenciador del Gen/fisiología , Inflamación/genética , Inflamación/metabolismo , Inflamación/fisiopatología , Leucotrienos/biosíntesis , Lipoxinas/biosíntesis , Masculino , Ratones , Ratones Endogámicos C57BL , Regiones Promotoras Genéticas/genética , ARN Mensajero/análisis , Mapeo Restrictivo/métodosRESUMEN
Although G protein-coupled MT1 and MT2 melatonin receptors are expressed in neurons of the mammalian brain including in humans, relatively little is known about the influence of native MT1 and MT2 melatonin receptors on neuronal melatonin signaling. Whereas human cerebellar granule cells (CGC) express only MT1 receptors, mouse CGC express both MT1 and MT2. To study the effects of altered neuronal MT1/MT2 receptors, we used CGC cultures prepared from immature cerebella of wild-type mice (MT1/MT2 CGC) and MT1- and MT2-knockout mice (MT2 and MT1 CGC, respectively). Here we report that in MT1/MT2 cultures, physiological (low nanomolar) concentrations of melatonin decrease the activity (phosphorylation) of extracellular-signal-regulated kinase (ERK) whereas a micromolar concentration was ineffective. Both MT1 and MT2 deficiencies transformed the melatonin inhibition of ERK into melatonin-induced ERK activation. In MT1/MT2 CGC, 1 nM melatonin inhibited serine/threonine kinase Akt, whereas in MT1 and MT2 CGC, this concentration was ineffective. Under these conditions, both MT1 and MT2 deficiencies prevented melatonin from inhibiting forskolin-stimulated cAMP levels and cFos immunoreactivity. We demonstrated that selective removal of native neuronal MT1 and MT2 receptors has a profound effect on the intracellular actions of low/physiological concentrations of melatonin. Since the expression of MT1 and MT2 receptors is cell-type-specific and species-dependent, we postulate that the pattern of expression of neuronal melatonin receptor types in different brain areas and cells could determine the capabilities of endogenous melatonin in regulating neuronal functioning.
Asunto(s)
Cerebelo/citología , Melatonina/farmacología , Neuronas/efectos de los fármacos , Receptor de Melatonina MT1/fisiología , Receptor de Melatonina MT2/fisiología , Transducción de Señal , Análisis de Varianza , Animales , Animales Recién Nacidos , Western Blotting , Células Cultivadas , AMP Cíclico/metabolismo , Relación Dosis-Respuesta a Droga , Quinasas MAP Reguladas por Señal Extracelular/metabolismo , Inmunohistoquímica , Melatonina/metabolismo , Ratones , Ratones Endogámicos C3H , Ratones Noqueados , Neuronas/citología , Neuronas/metabolismo , Fosforilación/efectos de los fármacos , Proteínas Serina-Treonina Quinasas/metabolismo , Proteínas Proto-Oncogénicas c-akt/metabolismo , Proteínas Proto-Oncogénicas c-fos/metabolismo , Receptor de Melatonina MT1/deficiencia , Receptor de Melatonina MT1/genética , Receptor de Melatonina MT2/deficiencia , Receptor de Melatonina MT2/genéticaRESUMEN
A common biological pathway may contribute to the comorbidity of atherosclerosis and depression. Increased activity of the enzymatic 5-lipoxygenase (5-LOX, 5LO) pathway is a contributing factor in atherosclerosis and a 5-LOX inhibitor, MK-886, is beneficial in animal models of atherosclerosis. In the brain, MK-886 increases phosphorylation of the glutamate receptor subunit GluR1, and the increased phosphorylation of this receptor has been associated with antidepressant treatment. In this work, we evaluated the behavioral effects of MK-886 in an automated assay of mouse forced swimming, which identifies antidepressant activity as increased climbing behavior and/or decreased rest time. Whereas a single injection of MK-886 (3 and 10 mg/kg) did not affect forced swimming behaviors assayed 30 min later, six daily injections of 3 mg/kg MK-886 slightly increased climbing and significantly reduced rest time in wild-type mice but not in 5-LOX-deficient mice. A diet delivery of MK-886, 4 micro/(100 mg(body-weight)day), required 3 weeks to affect forced swimming; it increased climbing behavior. Climbing behavior was also increased in naive 5-LOX-deficient mice compared to naive wild-type controls. These results suggest that 5-LOX inhibition and deficiency may be associated with antidepressant activity. Increased climbing in a forced swimming assay is a typical outcome of antidepressants that increase noradrenergic and dopaminergic activity. Interestingly, 5-LOX deficiency and MK-886 treatment have been shown to be capable of increasing the behavioral effects of a noradrenaline/dopamine-potentiating drug, cocaine. Future research is needed to evaluate the clinical relevance of our findings.
Asunto(s)
Araquidonato 5-Lipooxigenasa/deficiencia , Conducta Animal/efectos de los fármacos , Indoles/administración & dosificación , Inhibidores de la Lipooxigenasa/administración & dosificación , Natación , Animales , Relación Dosis-Respuesta a Droga , Vías de Administración de Medicamentos , Esquema de Medicación , Masculino , Ratones , Ratones Transgénicos , Movimiento/efectos de los fármacos , Factores de TiempoRESUMEN
Melatonin receptor activation has been linked to the regulation of neurotrophic factors, including the brain-derived neurotrophic factor (BDNF). To further characterize the effects of melatonin receptor stimulation on neuronal BDNF, we used a clinically available novel agonist for MT1 and MT2 melatonin receptors, ramelteon. Primary cultures of cerebellar granule cells (CGC) have been established as an in vitro model for studying neuronal BDNF. We took advantage of the availability of MT1- and MT2-deficient (knockout; KO) mice to employ primary CGC prepared from wild type (WT), MT1 KO, and MT2 KO mice. We investigated the effects of ramelteon on BDNF protein and mRNA content. Administered in a low nanomolar range, ramelteon increased BDNF protein content in all three types of mouse CGC. This ramelteon-triggered BDNF protein elevation was not preceded by a BDNF mRNA increase. However, it was prevented by treatment of cultures with a protein synthesis inhibitor cycloheximide. These results demonstrated that the MT1/MT2 melatonin receptor agonist ramelteon is capable of increasing BDNF protein in neurons expressing either of the two melatonin receptor types and that this action of ramelteon involves translational mechanisms. Further research is needed to explore the putative influence of ramelteon on BDNF-associated neuroplasticity.
Asunto(s)
Factor Neurotrófico Derivado del Encéfalo/metabolismo , Cerebelo/citología , Regulación de la Expresión Génica/efectos de los fármacos , Indenos/farmacología , Neuronas/efectos de los fármacos , Animales , Animales Recién Nacidos , Factor Neurotrófico Derivado del Encéfalo/clasificación , Factor Neurotrófico Derivado del Encéfalo/genética , Células Cultivadas , Cicloheximida/farmacología , Interacciones Farmacológicas , Regulación de la Expresión Génica/genética , Ratones , Ratones Noqueados , Inhibidores de la Síntesis de la Proteína/farmacología , ARN Mensajero/metabolismo , Receptor de Melatonina MT1/deficiencia , Receptor de Melatonina MT2/deficiencia , Factores de TiempoRESUMEN
The tetracycline antibiotic minocycline beneficially affects neuronal functioning and also inhibits the enzyme 5-lipoxygenase (5-LOX). We hypothesized that similar to 5-LOX inhibitors, minocycline may increase phosphorylation and membrane insertion of the glutamate receptor GluR1. The experiments were performed in primary cultures of mouse striatal neurons and in the prefrontal cortex and striatum of minocycline-treated mice. In vitro, low micromolar minocycline concentrations increased GluR1 phosphorylation at Ser845 and Ser831 and increased the surface content of GluR1. Minocycline also increased GluR1 phosphorylation in vivo. Increased GluR1 phosphorylation and minocycline treatment have been associated with antidepressant and memory-enhancing activities. Direct consequences of minocycline-increased GluR1 phosphorylation are yet to be established.
Asunto(s)
Inhibidores de la Lipooxigenasa/farmacología , Minociclina/farmacología , Neuronas/efectos de los fármacos , Receptores AMPA/metabolismo , Análisis de Varianza , Animales , Encéfalo/citología , Células Cultivadas , Relación Dosis-Respuesta a Droga , Embrión de Mamíferos , Masculino , Ratones , Ratones Endogámicos C57BL , Fosforilación/efectos de los fármacos , Serina/metabolismoRESUMEN
Modifications of AMPA glutamate receptor GluR1 phosphorylation are critical for neuroplastic mechanisms. Previous in vitro studies in brain slices employed MK-886, a functional inhibitor of the enzyme 5-lipoxygenase (5-LOX), and found increased GluR1 phosphorylation. Since slice preparations have accompanying postmortem phosphorylation changes, e.g., decreased GluR1 phosphorylation, it remains to be clarified whether MK-886 can affect GluR1 phosphorylation in intact neurons and in the brain in vivo. We used primary neuronal cultures prepared from embryonic mouse brain and in vivo drug administration to investigate the effects of MK-886 on GluR1 phosphorylation using quantitative Western immunoblotting assays. In vitro, MK-886 increased GluR1 phosphorylation at both serine 831 and serine 845. In vivo, repeated but not a single MK-886 injection increased GluR1 phosphorylation in the prefrontal cortex. These findings indicate that MK-886 has an intrinsic effect on neuronal phosphorylation both in vitro and in vivo and support the use of MK-886 as a pharmacological tool in studies of not only the 5-LOX pathway but also neuronal GluR1 functioning.
Asunto(s)
Indoles/farmacología , Inhibidores de la Lipooxigenasa/farmacología , Neuronas/metabolismo , Corteza Prefrontal/metabolismo , Receptores AMPA/metabolismo , Animales , Araquidonato 5-Lipooxigenasa/metabolismo , Células Cultivadas , Masculino , Ratones , Ratones Endogámicos C57BL , Neuronas/efectos de los fármacos , Fosforilación , Corteza Prefrontal/citología , Corteza Prefrontal/efectos de los fármacosRESUMEN
The pineal hormone melatonin produces most of its biological effects via G protein-coupled receptors MT1 and MT2. In mammals, these receptors are expressed in various tissues and organs including in the brain. Recent research points to a putative role of MT1/MT2 dimerization as a mechanism that could determine the receptor-mediated biological effects of melatonin. Brain content and the ratios between MT1 and MT2 receptors are affected by illness, e.g., Alzheimer's disease, and by prolonged drug treatment, e.g., antidepressants. New drugs with antidepressant properties that bind and activate melatonin receptors have been discovered. We hypothesize that endogenous, i.e., low, levels of melatonin could contribute to antidepressant effects depending on the expression pattern of melatonin receptors in the brain. Hence, we propose that a prolonged treatment with classical antidepressant drugs alters the brain ratio of MT1/MT2 receptors to enable the endogenous melatonin, which is secreted during the night, to further improve the antidepressant effects. A corollary of this hypothesis is that antidepressants would be less effective in conditions of pathologically altered brain melatonin receptors, e.g., in Alzheimer's patients or due to genetic polymorphisms. If our hypothesis is confirmed, supplementing classical antidepressant treatment with an appropriate dose of a melatonin receptor agonist might be used to improve antidepressant effects in subjects with a susceptible pattern of brain melatonin receptor expression.
Asunto(s)
Antidepresivos/administración & dosificación , Encéfalo/metabolismo , Depresión/tratamiento farmacológico , Depresión/metabolismo , Melatonina/metabolismo , Modelos Neurológicos , Receptores de Melatonina/metabolismo , Encéfalo/efectos de los fármacos , Expresión Génica/efectos de los fármacos , Humanos , Receptores de Melatonina/efectos de los fármacos , Distribución Tisular , Resultado del TratamientoRESUMEN
AIMS: Sirtuins connect energy generation and metabolic stress to the cellular acetylome. Currently, only the mitochondrial sirtuins (SIRT3-5) and SIRT1 have been shown to direct mitochondrial function; however, Aims: NAD-dependent protein deacetylase sirtuin-2 (SIRT2), the primary cytoplasmic sirtuin, is not yet reported to associate with mitochondria. RESULTS: This study revealed a novel physiological function of SIRT2: the regulation of mitochondrial function. First, the acetylation of several metabolic mitochondrial proteins was found to be altered in Sirt2-deficient mice, which was, subsequently, validated by immunoprecipitation experiments in which the acetylated mitochondrial proteins directly interacted with SIRT2. Moreover, immuno-gold electron microscopic images of mouse brains showed that SIRT2 associates with the inner mitochondrial membrane in central nervous system cells. The loss of Sirt2 increased oxidative stress, decreased adenosine triphosphate levels, and altered mitochondrial morphology at the cellular and tissue (i.e., brain) level. Furthermore, the autophagic/mitophagic processes were dysregulated in Sirt2-deficient neurons and mouse embryonic fibroblasts. INNOVATION: For the first time it is shown that SIRT2 directs mitochondrial metabolism. CONCLUSION: Together, these findings support that SIRT2 functions as a mitochondrial sirtuin, as well as a regulator of autophagy/mitophagy to maintain mitochondrial biology, thus facilitating cell survival. Antioxid. Redox Signal. 26, 849-863.
Asunto(s)
Mitocondrias/metabolismo , Proteínas Mitocondriales/metabolismo , Mitofagia , Sirtuina 2/deficiencia , Acetilación , Animales , Células Cultivadas , Humanos , Ratones , Ratones Noqueados , Sirtuina 2/genética , Sirtuina 2/metabolismoRESUMEN
The pineal product melatonin that acts on specific melatonin receptors has been implicated in pathobiological mechanisms of neuropsychiatric disorders including Alzheimer's disease. We used mice lacking melatonin MT(2) receptors (MT(2) knockouts) to investigate the role of these receptors in synaptic plasticity and learning-dependent behavior. In field CA1 of hippocampal slices from wild-type mice, theta burst stimulation induced robust and stable long-term potentiation that was smaller and decremental in slices from MT(2) knockouts. Tested in an elevated plus-maze on two consecutive days, wild-type mice showed shorter transfer latencies to enter a closed arm on the second day; this experience-dependent behavior did not occur in MT(2) knockouts. These results suggest that MT(2) receptors participate in hippocampal synaptic plasticity and in memory processes.
Asunto(s)
Hipocampo/fisiología , Potenciación a Largo Plazo/fisiología , Receptor de Melatonina MT2/deficiencia , Receptor de Melatonina MT2/fisiología , Animales , Conducta Animal , Relación Dosis-Respuesta en la Radiación , Estimulación Eléctrica/métodos , Potenciales Postsinápticos Excitadores/genética , Potenciales Postsinápticos Excitadores/efectos de la radiación , Técnicas In Vitro , Potenciación a Largo Plazo/efectos de la radiación , Masculino , Aprendizaje por Laberinto/fisiología , Ratones , Ratones Noqueados , Tiempo de Reacción/genéticaRESUMEN
The physiological effects of pineal melatonin are primarily mediated by melatonin receptors located in the brain and periphery. Even though there are a number of studies demonstrating the regulatory role of melatonin in the development of dopaminergic behaviors, such as psychostimulant-induced diurnal locomotor sensitization or drug seeking, little is known about the contribution of melatonin receptors (i.e., MT1) to this role. Therefore, as a first step in understanding the functional role of melatonin receptors in dopaminergic behaviors, we focused on determining the expression pattern of MT1 receptors in the dopaminergic system of the human and rodent brain. Regional (e.g., nucleus accumbens shell) and cellular (e.g., tyrosine hydroxylase immunopositive cells) expression of MT1 mRNA was characterized by applying the immuno-laser capture microdissection (immuno-LCM) technique coupled with nested RT-PCR. Moreover, employing quantitative Western immunoblotting and RT-PCR, we found that the mouse MT1 receptor expression presents diurnal variations (i.e., low mRNA and high protein levels at night, ZT21). The dopaminergic system-based presence of MT1 receptor proteins was not limited to rodents; we found these receptors in postmortem human brain as well. Further research is needed to understand the regional/cellular functional role of melatonin receptors in the regulation of dopaminergic behaviors, using models such as melatonin receptor knockout mice.
Asunto(s)
Encéfalo/citología , Dopamina/metabolismo , Regulación de la Expresión Génica/fisiología , Neuronas/metabolismo , Receptor de Melatonina MT1/metabolismo , Animales , Northern Blotting/métodos , Western Blotting/métodos , Ritmo Circadiano/fisiología , Humanos , Inmunohistoquímica/métodos , Masculino , Ratones , Microdisección/métodos , ARN Mensajero/biosíntesis , Ratas , Receptor de Melatonina MT1/genética , Receptores de Dopamina D2/genética , Receptores de Dopamina D2/metabolismo , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa/métodos , Tirosina 3-Monooxigenasa/metabolismoRESUMEN
Gamma-hydroxybutyric acid (GHB) can be synthesized in the brain but is also a known drug of abuse. Although putative GHB receptors have been cloned, it has been proposed that, similar to the behavior-impairing effects of ethanol, the in vivo effects of pharmacological GHB may involve metabotropic gamma-aminobutyric acid (GABA) GABA(B) receptors. We developed a fruitfly (Drosophila melanogater) model to investigate the role of these receptors in the behavioral effects of exogenous GHB. Injecting GHB into male flies produced a dose-dependent motor impairment (measured with a computer-assisted automated system), which was greater in ethanol-sensitive cheapdate mutants than in wild-type flies. These effects of pharmacological concentrations of GHB require the presence and activation of GABA(B) receptors. The evidence for this was obtained by pharmacological antagonism of GABA(B) receptors with CGP54626 and by RNA interference (RNAi)-induced knockdown of the GABA(B(1)) receptor subtype. Both procedures inhibited the behavioral effects of GHB. GHB pretreatment diminished the behavioral response to subsequent GHB injections; i.e., it triggered GHB tolerance, but did not produce ethanol tolerance. On the other hand, ethanol pretreatment produced both ethanol and GHB tolerance. It appears that in spite of many similarities between ethanol and GHB, the primary sites of their action may differ and that recently cloned putative GHB receptors may participate in actions of GHB that are not mediated by GABA(B) receptors. These receptors do not have a Drosophila orthologue. Whether Drosophila express a different GHB receptor should be explored.
Asunto(s)
Conducta Animal/efectos de los fármacos , Drosophila melanogaster/efectos de los fármacos , Hidroxibutiratos/farmacología , Receptores de GABA-B/fisiología , Animales , Benzocicloheptenos/farmacología , Relación Dosis-Respuesta a Droga , Drosophila melanogaster/genética , Drosophila melanogaster/fisiología , Interacciones Farmacológicas , Etanol/farmacología , Antagonistas de Receptores de GABA-B , Masculino , Actividad Motora/efectos de los fármacos , Mutación , Compuestos Organofosforados/farmacología , Interferencia de ARN , ARN Bicatenario/farmacología , Receptores de GABA-B/genética , Factores de TiempoRESUMEN
Previously, an RNA interference (RNAi) knockdown of GABAB(1) subunit in adult Drosophila was used for behavioral studies. Here we report on developmental deficits caused by embryonic Drosophila GABAB(1) RNAi and drug antagonism. Injecting embryos with CGP54626 (a GABAB receptor antagonist) reduced hatching and caused lethality. Similar effects were produced by injecting embryos with GABAB(1) double-stranded RNA (RNAi). The surviving GABAB(1) RNAi larvae were significantly smaller than controls and showed a peculiar phenotype; their tracheae were folded. Our results suggest that GABAB receptors are required for normal development and that the Drosophila model could be used to investigate the participating molecular mechanisms.
Asunto(s)
Desarrollo Embrionario/fisiología , Receptores de GABA-B/deficiencia , Receptores de GABA-B/fisiología , Animales , Animales Modificados Genéticamente , Northern Blotting/métodos , Drosophila , Desarrollo Embrionario/efectos de los fármacos , Desarrollo Embrionario/genética , Antagonistas del GABA/farmacología , Larva , Compuestos Organofosforados/farmacología , Fenotipo , ARN Bicatenario/farmacología , ARN Mensajero/biosíntesis , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa/métodosRESUMEN
Fluoxetine produces initial paradoxical anxiogenic effect in some patients. In an elevated plus-maze (EPM), fluoxetine triggers an anxiogenic-like effect in rodents. Behavioral responses to psychoactive drugs can be modified by the pineal gland. We assessed the actions of fluoxetine in the EPM in melatonin-proficient C3H mice, melatonin-deficient C57BL6 mice, and in sham-operated and pinealectomized mice. Mice were assayed 30 min after the first injection and on day 14. Protracted fluoxetine treatment reduced the time on the anxiogenic open arms and increased the entries into the safe closed arms in sham-operated C3H mice. Fluoxetine was ineffective in pinealectomized C3H or C57BL6 mice. It is possible that the pineal system contributes to the previously observed anxiogenic action of fluoxetine in humans.
Asunto(s)
Trastornos de Ansiedad/inducido químicamente , Fluoxetina/efectos adversos , Glándula Pineal/efectos de los fármacos , Animales , Trastornos de Ansiedad/metabolismo , Trastornos de Ansiedad/fisiopatología , Arilamina N-Acetiltransferasa/efectos de los fármacos , Arilamina N-Acetiltransferasa/metabolismo , Desnervación , Masculino , Melatonina/metabolismo , Ratones , Ratones Endogámicos C3H , Ratones Endogámicos C57BL , Glándula Pineal/metabolismo , ARN Mensajero/efectos de los fármacos , ARN Mensajero/metabolismo , Serotonina/metabolismo , Especificidad de la EspecieRESUMEN
Fluvoxamine, a selective serotonin re-uptake inhibitor, is used as antidepressant/anxiolytic. The presence of a C=N double bond in the structure of fluvoxamine implies the existence of two geometric isomers: E- (trans) and Z- (cis), and suggests the hypothetical susceptibility of the molecule to photoisomerization. Clinically effective fluvoxamine is in its trans form. UVB (ultraviolet light, class B, wavelength range 290-320 nm) irradiation of aqueous solutions of fluvoxamine generated a photoproduct, which was isolated and analyzed by nuclear magnetic resonance (NMR) and mass spectrometry (MS), and identified as the cis isomer of fluvoxamine. This cis-isomer lost capacity to inhibit serotonin uptake, suggesting that light exposure might reduce the clinical efficacy of fluvoxamine. Alternatively, the photoproduct could be used as an inactive isomer in the studies of antidepressant mechanisms. Recent proposal suggests that antidepressants increase neurogenesis in the adult brain, whereas either an inhibitory or a stimulatory action of antidepressants on [(3)H]thymidine uptake in vitro has been attributed to their interaction with serotonergic mechanisms. Lower concentrations (i.e., 2 microM) of fluvoxamine and fluoxetine (another selective serotonin re-uptake inhibitor) stimulated [(3)H]thymidine uptake in mature, but inhibited it in immature cultures of rat cerebellar granule cells; the photoproduct was ineffective. A high concentration of fluvoxamine (i.e., 20 microM) but not the photoproduct was toxic to both immature and mature cultures. We suggest that a mechanism sensitive to fluvoxamine photoisomerization might be involved in the action of antidepressants on cell proliferation.
Asunto(s)
Antidepresivos de Segunda Generación/química , Fluvoxamina/química , Rayos Ultravioleta , Animales , Animales Recién Nacidos , Antidepresivos de Segunda Generación/farmacología , Antidepresivos de Segunda Generación/efectos de la radiación , Encéfalo/citología , Encéfalo/ultraestructura , División Celular/efectos de los fármacos , Células Cultivadas , Cromatografía Líquida de Alta Presión , Cromatografía en Capa Delgada , Estabilidad de Medicamentos , Fluoxetina/química , Fluvoxamina/farmacología , Fluvoxamina/efectos de la radiación , Técnicas In Vitro , Masculino , Fotoquímica , Ratas , Ratas Sprague-Dawley , Serotonina/metabolismo , Estereoisomerismo , Sinaptosomas/efectos de los fármacos , Sinaptosomas/metabolismoRESUMEN
Although melatonin affects developing neurons and is neuroprotective, a role of melatonin receptors termed MT1 and MT2 in these actions is unclear. We investigated the effects of melatonin on the levels of the brain derived neurotrophic factor (BDNF) in the developing cerebellum and cerebellar granule cells (CGC) of wild-type (WT), MT1- and MT2-knockout mice. A model of low-potassium CGC toxicity was used to evaluate neuroprotection. A 14-day-old pups and CGC cultures were treated with melatonin; 0.01 mg/kg intraperitoneally and 1 nM in vitro, respectively. Treatment of WT pups and CGC with melatonin did not alter BDNF levels. The absence of MT2 but not MT1 receptors enabled melatonin to increase cerebellar and CGC BDNF content. Nanomolar melatonin was neuroprotective in MT2-knockout but not WT CGC. We propose that CGC from MT2-knockout mice could serve as a model for studying the influence of melatonin on human CGC, which express MT1 but not MT2 receptors.
Asunto(s)
Factor Neurotrófico Derivado del Encéfalo/farmacología , Cerebelo/citología , Melatonina/farmacología , Neuronas/efectos de los fármacos , Fármacos Neuroprotectores/farmacología , Receptores de Melatonina/efectos de los fármacos , Animales , Células Cultivadas , Cerebelo/efectos de los fármacos , Ratones , Ratones Endogámicos C3H , Ratones Noqueados , ARN Mensajero/biosíntesis , ARN Mensajero/genética , Receptor de Melatonina MT1/efectos de los fármacos , Receptor de Melatonina MT1/genética , Receptor de Melatonina MT2/efectos de los fármacos , Receptor de Melatonina MT2/genética , Sales de Tetrazolio , TiazolesRESUMEN
Caffeic acid is a natural compound that inhibits 5-lipoxygenase (5-LOX). In mice, caffeic acid produces antidepressant-like effects and attenuates the decrease in cortical brain-derived neurotrophic factor (BDNF) mRNA induced by forced swimming. We used wild-type and 5-LOX-deficient mice and found that swimming reduced the cortical content of BDNF exon IV but not exon I mRNA. The BDNF transcript IV decrease was attenuated by caffeic acid in wild-type but not in 5-LOX-deficient mice, suggesting a role for 5-LOX in BDNF regulation.
Asunto(s)
Araquidonato 5-Lipooxigenasa/genética , Factor Neurotrófico Derivado del Encéfalo/genética , Ácidos Cafeicos/farmacología , Corteza Cerebral/efectos de los fármacos , ARN Mensajero/efectos de los fármacos , Estrés Psicológico/tratamiento farmacológico , Animales , Antidepresivos/metabolismo , Antidepresivos/farmacología , Antioxidantes/metabolismo , Antioxidantes/farmacología , Ácido Araquidónico/biosíntesis , Química Encefálica/efectos de los fármacos , Química Encefálica/genética , Ácidos Cafeicos/metabolismo , Corteza Cerebral/metabolismo , Corteza Cerebral/fisiopatología , Trastorno Depresivo/tratamiento farmacológico , Trastorno Depresivo/genética , Trastorno Depresivo/metabolismo , Regulación hacia Abajo/efectos de los fármacos , Regulación hacia Abajo/genética , Regulación de la Expresión Génica/efectos de los fármacos , Regulación de la Expresión Génica/genética , Masculino , Ratones , Ratones Noqueados , ARN Mensajero/metabolismo , Estrés Psicológico/genética , Estrés Psicológico/metabolismo , Transcripción Genética/efectos de los fármacos , Transcripción Genética/genéticaRESUMEN
OBJECTIVES: In the mammalian brain, G protein-coupled MT(1) and MT(2) melatonin receptors may be involved in Alzheimer's pathology, long-term potentiation, depression, and in the behavioral effects of psychoactive drugs. These drugs; e.g. antidepressants and drugs of abuse, are typically used over long periods of time and may alter neuroplasticity and gene expression. We hypothesized that such antidepressant- and cocaine-altered expression of melatonin receptor mRNA may occur in the hippocampus and striatum. METHODOLOGY: Male C3H/HeJ mice were treated with the antidepressants fluoxetine, desipramine, and clomipramine, with the psychostimulant cocaine, and with a vehicle either a single time or once a day for 14 days. Brain samples were collected 24 h after the last injection and the content of MT(1) and MT(2) mRNA was assayed. RESULTS: A single drug injection did not alter the MT(1) and MT(2) mRNA content. In the hippocampus, protracted treatment with antidepressants increased the amount of MT(1) mRNA (with the exception of fluoxetine) but decreased MT(2) mRNA content; cocaine did not produce any alterations. In the striatum, antidepressants produced the opposite effect on MT(1) mRNA content; they decreased it. They did not significantly alter striatal MT(2) mRNA (we observed a nonsignificant trend to a decrease). Cocaine also decreased striatal MT(1) mRNA content without affecting MT(2) mRNA. CONCLUSION: These results suggest that drug- and region-specific alterations of MT(1)/MT(2) mRNA produced by protracted antidepressants and cocaine treatment may alter MT1/MT2 expression and contribute to long-term neuroplastic effects of these drugs.